.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Mallinckrodt
McKinsey
Colorcon
Boehringer Ingelheim
Novartis
Citi
Medtronic
Deloitte
Chinese Patent Office

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,547,656

« Back to Dashboard

Summary for Patent: 5,547,656

Title: Low density microspheres and their use as contrast agents for computed tomography, and in other applications
Abstract:Substantially homogeneous aqueous suspensions of low density microspheres are presented as contrast media for imaging the gastrointestinal tract and other body cavities using computed tomography. In one embodiment, the low density microspheres are gas-filled. With computed tomography, the contrast media serve to change the relative density of certain areas within the gastrointestinal tract and other body cavities, and improve the overall diagnostic efficacy of this imaging method.
Inventor(s): Unger; Evan C. (Tucson, AZ)
Assignee: Imarx Pharmaceutical Corp. (Tucson, AZ)
Application Number:08/449,090
Patent Claim Types:
see list of patent claims
Delivery; Compound; Device; Use;

No matches for this query

International Patent Family for Patent: 5,547,656

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark0580726► Subscribe
Denmark0804932► Subscribe
European Patent Office0762899► Subscribe
European Patent Office0580726► Subscribe
European Patent Office0760684► Subscribe
Germany69231830► Subscribe
Germany69229342► Subscribe
China1160357► Subscribe
China1149259► Subscribe
Canada2191079► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
McKinsey
Fuji
Colorcon
Novartis
Citi
Deloitte
UBS
Farmers Insurance
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot